WE DO NOT SHIP TO RESIDENTIAL ADDRESSES. For pricing in CAD/AUD/NZD please contact us.

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)(Active) - PKSH033573

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)(Active) - PKSH033573

Regular price
$207.20
Regular price
Sale price
$207.20
Unit price
per 
Availability
Sold out

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)(Active)

Size: 50μg

Catalogue Number: PKSH033573-50

Citations, Manuals and MSDS Available upon request.

Abbreviation: Osteoprotegerin; TNFRSF11B

Target Symptom: Tumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF11B; OCIF; OPG; PDB5; TR1

Research Area: Signal Transduction; Cardiovascular; immunology; metabolism;

Target Species: Human

Expression Host: HEK293 Cells

Application: Cell culture

Fusion Tag: C-His

UNIProt ID: O00300

Accession: O00300

Background: TNFRSF11B is a secreted protein; containing 2 death domains and 4 TNFR-Cys repeats. TNFRSF11B is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL; TNFRSF11B inhibits nuclear kappa B (NF-κB) which is a central and rapid acting transcription factor for immune-related genes; and a key regulator of inflammation; innate immunity; and cell survival and differentiation. TNFRSF11B levels are influenced by voltage-dependent calcium channelsCav1.2. TNFRSF11B can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitroand in vivo. TNFRSF11B binding to RANKL on osteoblast/stromal cells; blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.

Activity: Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 10.6 ng/ml.

Sequence: Glu22-Leu401

Purity: > 95 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 44.65 kDa

Observed MW: 57 kDa

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Research Use Only